- Home
- HIX vs OABI Comparison
HIX vs OABI Comparison
Compare HIX & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HIX | OABI |
|---|---|---|
| Founded | 1998 | 2012 |
| Country | United States | United States |
| Employees | N/A | 89 |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 356.7M | 391.4M |
| IPO Year | 1998 | N/A |
Fundamental Metrics
Financial Performance| Metric | HIX | OABI |
|---|---|---|
| Price | $3.95 | $2.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 278.6K | ★ 560.5K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 13.14% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $52.42 |
| Revenue Next Year | N/A | $64.69 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.75 | $1.32 |
| 52 Week High | $4.39 | $2.79 |
Technical Indicators
Market Signals| Indicator | HIX | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 49.23 | 53.76 |
| Support Level | $3.89 | $1.42 |
| Resistance Level | $4.04 | $2.79 |
| Average True Range (ATR) | 0.04 | 0.19 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 46.67 | 68.02 |
Price Performance
Historical ComparisonAbout HIX Western Asset High Income Fund II Inc.
Western Asset High Income Fund II Inc is a diversified closed-end management investment company. Its primary investment objective is to maximize current income by investing at least 80% of its net assets, plus any borrowings for investment purposes, in high-yield debt securities. As a secondary objective, the Fund seeks capital appreciation to the extent consistent with its objective of seeking to maximize current income.
About OABI OmniAb Inc.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.